Study 506-Second Interim Analysis of a Retrospective, Phase IV Study of Perampanel in Real-World Clinical Care of Patients with Epilepsy: Adolescent Subgroup (Aged 12 to <18 Years)

被引：0
|
作者：
Segal, Eric [1 ]
Wheless, James [2 ]
Moretz, Katherine [3 ]
Penovich, Patricia [4 ]
Patten, Anna [5 ]
Williams, Betsy [6 ]
Malhotra, Manoj [6 ]
机构：
[1] Northeast Reg Epilepsy Grp, Hackensack, NJ USA
[2] Univ Tennessee, Le Bonheur Childrens Hosp, Memphis, TN USA
[3] Meridian Clin Res LLC, Savannah, GA USA
[4] Minnesota Epilepsy Grp PA, St Paul, MN USA
[5] Eisai Ltd, Hatfield, Herts, England
[6] Eisai Ltd, Woodcliff Lake, NJ USA
来源：
NEUROLOGY | 2019年 / 92卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P5.5-017
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Efficacy and safety of adjunctive perampanel treatment in pediatric patients with epilepsy aged 4-12 years: a real-world study
    Zeng, Qiao
    Xia, Xueqian
    Jiang, Li
    Chen, Jin
    Liu, Yuhang
    Hu, Yue
    JOURNAL OF NEUROLOGY, 2024, 271 (07) : 4566 - 4576
  • [22] Real-World Effectiveness of Damoctocog Alfa Pegol in the Subgroup of Adolescent Hemophilia A Patients Aged 12-18 Years in the ATHNdataset
    Chandler, Martin
    Recht, Michael
    He, Chunla
    Moulton, Thomas
    Charafi, Lena
    BLOOD, 2021, 138
  • [23] Efficacy, safety, and tolerability of adjunctive perampanel in the treatment of pediatric patients aged 4-18 years with epilepsy: A single-center, retrospective, observational real-world study
    Weng, Yijun
    Rao, Xin
    Ma, Bihong
    Lin, Xi
    BRAIN & DEVELOPMENT, 2025, 47 (01):
  • [24] Perampanel as only add-on epilepsy treatment in elderly: A subgroup analysis of real-world data from retrospective, multicenter, observational study
    Pascarella, Angelo
    Gasparini, Sara
    Manzo, Lucia
    Marsico, Oreste
    Torino, Claudia
    Abelardo, Domenico
    Cianci, Vittoria
    Iudice, Alfonso
    Bisulli, Francesca
    Bonanni, Paolo
    Caggia, Emanuele
    D'Anielloi, Alfredo
    Di Bonaventura, Carlo
    Difrancesco, Jacopo C.
    Domina, Elisabetta
    Dono, Fedele
    Gambardella, Antonio
    Marini, Carla
    Marrelli, Alfonso
    Matricardi, Sara
    Morano, Alessandra
    Paladin, Francesco
    Renna, Rosaria
    Piccioli, Marta
    Striano, Pasquale
    Ascoli, Michele
    Ferlazzo, Edoardo
    Aguglia, Umberto
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [25] Long-term efficacy and safety of adjunctive perampanel in pediatric patients aged 4–19 years with epilepsy: a real-world study
    Song Ee Youn
    Hoon-Chul Kang
    Joon Soo Lee
    Heung Dong Kim
    Se Hee Kim
    Scientific Reports, 13
  • [26] Study 508: A phase IV, post-approval study of adjunctive perampanel in Indian patients aged ≥12 years with epilepsy based on seizure type
    Ravat, Sangeeta
    Kulkarni, Rahul
    Rohatgi, Anshu
    Ghosh, Pahari
    Patil, Balaji
    Dash, Amitabh
    Malhotra, Manoj
    EPILEPSIA, 2021, 62 : 48 - 49
  • [27] Perampanel Monotherapy for the Treatment of Epilepsy: Evidence From a Clinical Trial (Study 342) and Real-World Use (Studies 504 and 506)
    Gil-Nagel, Antonio
    Wheless, James
    Kim, Ji Hyun
    Wechsler, Robert T.
    Yamamoto, Takamichi
    EPILEPSIA, 2021, 62 : 50 - 51
  • [28] Perampanel Monotherapy for the Treatment of Epilepsy: Evidence From a Clinical Trial (Study 342) and Real-World Use (Studies 504 and 506)
    Gil-Nagel, Antonio
    Wheless, James
    Kim, Ji Hyun
    Wechsler, Robert T.
    Yamamoto, Takamichi
    NEUROLOGY, 2021, 96 (15)
  • [29] Perampanel in adult epilepsy patients treated in everyday clinical practice: results from an interim pooled analysis of real-world studies
    Strzelczyk, Adam
    Wehner, Tim
    Deleo, Francesco
    Carreno, Mar
    Trinka, Eugen
    Wu, Tony
    Dash, Amitabh
    Villanueva, Vicente
    EPILEPSIA, 2021, 62 : 150 - 150
  • [30] Long-term efficacy and safety of adjunctive perampanel in pediatric patients aged 4-19 years with epilepsy: a real-world study
    Youn, Song Ee
    Kang, Hoon-Chul
    Lee, Joon Soo
    Kim, Heung Dong
    Kim, Se Hee
    SCIENTIFIC REPORTS, 2023, 13 (01)
12345